Aurinia Pharmaceuticals Inc.AUPHNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +24.32% | +32.76% | +24.18% | +22.41% | +8.41% |
| Gross Profit Growth | +29.30% | +36.81% | +26.65% | +30.26% | +5.23% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +274.21% | +76.14% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +153.19% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +2879.64% | +119.87% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +1500.00% | +140.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +1400.00% | +133.50% |
| Weighted Average Shares Growth | +0.14% | -1.01% | -3.54% | -3.08% | -4.11% |
| Weighted Average Shares Diluted Growth | +1.96% | +2.82% | -3.54% | -0.63% | -6.62% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +110.41% | +0.00% | +179.25% | +161.02% |
| Free Cash Flow Growth | +0.00% | +110.89% | +0.00% | +180.90% | +161.95% |
| Receivables Growth | -3.86% | +51.70% | +39.58% | +57.08% | -15.23% |
| Inventory Growth | +17.96% | -1.20% | +16.18% | +19.69% | +15.70% |
| Asset Growth | -1.02% | +0.47% | -2.28% | -4.00% | -3.97% |
| Book Value per Share Growth | -1.13% | +0.89% | +0.99% | -5.12% | -1.69% |
| Debt Growth | -5.75% | -18.69% | -12.00% | -4.83% | -10.97% |
| R&D Expense Growth | -77.60% | -20.74% | +3.46% | +82.16% | +176.83% |
| SG&A Expenses Growth | -17.00% | -9.62% | -57.36% | -42.10% | -33.95% |